Search
Meet the team at Phage WA, who are working to tackle antimicrobial resistance (AMR) through phage therapy.
Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.
As part of our research development and planning we invite members of the community to work with us. Click here to find out how.
If you have any questions or would like more information about the Western Australian Epithelial Research Program (WAERP), please click here to access our contact details.
The Wal-yan Respiratory Research Centre is a global epicentre for paediatric respiratory research, informing clinical practice and driving a new research agenda for childhood lung health.
Antimicrobial resistance is a current global health crisis, and the increasing emergence of multidrug resistant infections has led to the resurgent interest in bacteriophages as an alternative treatment.
The purpose of this paper is to highlight a perspective for decolonizing research with Australian First Nations and provide a framework for successful and sustained knowledge translation by drawing on the recent work conducted by a research group, in five remote communities in North-Western Australia.
Neutrophils are key cells of the innate immune system. It is now understood that this leukocyte population is diverse in both the basal composition and functional plasticity. Underlying this plasticity is a post-translational framework for rapidly achieving early activation states, but also a transcriptional capacity that is becoming increasingly recognized by immunologists.
Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis complicating cystic fibrosis.
Aspergillus is increasingly associated with lung inflammation and mucus plugging in early cystic fibrosis disease during which conidia burden is low and strains appear to be highly diverse. It is unknown whether clinical Aspergillus strains vary in their capacity to induce epithelial inflammation and mucus production.